首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1506572篇
  免费   124316篇
  国内免费   6793篇
耳鼻咽喉   18624篇
儿科学   47302篇
妇产科学   39563篇
基础医学   206380篇
口腔科学   40030篇
临床医学   138493篇
内科学   311561篇
皮肤病学   35089篇
神经病学   126387篇
特种医学   62619篇
外国民族医学   345篇
外科学   235482篇
综合类   33921篇
现状与发展   2篇
一般理论   550篇
预防医学   120699篇
眼科学   31937篇
药学   104819篇
  5篇
中国医学   2461篇
肿瘤学   81412篇
  2019年   12275篇
  2018年   17080篇
  2017年   13517篇
  2016年   16026篇
  2015年   17906篇
  2014年   25089篇
  2013年   36866篇
  2012年   46671篇
  2011年   49950篇
  2010年   30806篇
  2009年   29926篇
  2008年   46360篇
  2007年   49233篇
  2006年   50237篇
  2005年   48735篇
  2004年   46240篇
  2003年   44651篇
  2002年   42328篇
  2001年   68435篇
  2000年   70108篇
  1999年   59044篇
  1998年   18759篇
  1997年   16678篇
  1996年   17428篇
  1995年   17511篇
  1994年   16281篇
  1993年   15214篇
  1992年   48647篇
  1991年   47244篇
  1990年   45320篇
  1989年   43124篇
  1988年   39969篇
  1987年   39193篇
  1986年   36968篇
  1985年   35756篇
  1984年   27436篇
  1983年   23063篇
  1982年   14864篇
  1981年   13386篇
  1980年   12546篇
  1979年   24437篇
  1978年   17908篇
  1977年   15052篇
  1976年   13865篇
  1975年   14289篇
  1974年   16797篇
  1973年   16055篇
  1972年   14756篇
  1971年   13507篇
  1970年   12347篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Abstract: Background: The identification of an autoimmune mechanism for many patients with chronic idiopathic urticaria (CIU) was used as a rational for a controlled clinical trial of cyclosporine for adults with CIU not responsive to usual measures. That randomized placebo controlled clinical trial demonstrated clinical efficacy, acceptable safety, and a suggestion of inducing remission in such patients. Objective: To report our experience with cyclosporine in pediatric patients with CIU. Methods: Fifty‐four patients with CIU were referred to us during the period from 2000 through June of 2005. Seven of those, aged 9–16, failed therapy with high dose antihistamines even with the addition of alternate morning prednisone. Neoral brand of cyclosporine, 3 mg/kg/day divided b.i.d., was initiated in these patients. Cyclosporine serum concentrations, blood urea nitrogen (BUN), creatinine, and blood pressure were routinely monitored. Results: All had cessation of hives. This occurred after 1–4 weeks for six of the seven and 8 weeks for one. While some experienced relapses, all were eventually off of all medications and free of hives. None of the seven experienced any adverse effects. Conclusions: Our experience in children is consistent with a previous controlled clinical trial in adults and supports the efficacy and safety of cyclosporine for CIU. However, we recommend that it be reserved for those whose CIU that is resistant to conventional measures and that patients be carefully monitored with cyclosporine serum concentrations and measures of renal function.  相似文献   
992.
Several cases of relapsing attacks during which the ear becomes red and patients experience a burning sensation have been reported in the literature. This combination of symptoms has been described as ‘red ear syndrome’ (RES). We report on a 7‐year‐old boy who had episodes of reddening, swelling and a burning sensation in one ear with local hyperthermia persisting for 3 years. The differential diagnosis included RES and erythromelalgia, as isolated auricular variants of erythromelalgia have been described and the symptoms are difficult to distinguish from RES. In this report, we discuss the similarities and differences between RES and erythromelalgia.  相似文献   
993.
994.
Abstract:  In Sweet's syndrome, the essential features are the characteristic morphology of the lesions, their histologic appearance, the dramatic response to corticosteroids and the absence of scarring. We report an 8-month-old infant in whom Sweet's syndrome was diagnosed and who developed acquired cutis laxa in the skin lesions.  相似文献   
995.
We report a case of localized bullous pemphigoid (BP) in a woman patient with primary lymphoedema tarda. There is only one previous case reported of localized pemphigoid in an area of lymphoedema, this being of the cicatricial variant. Slow circulation in the lymphatic vessels, increased capillary permeability with preferential localization of antibodies in the area, and potential cleavage of the epidermal junction due to increased hydrostatic pressure leading to autoimmunity, have all been advocated as possible pathogenic mechanisms. Nevertheless, we consider that the mechanism by which localized pemphigoid arises on lymphoedema remains elusive, based on a previous case of generalized BP sparing an area of postsurgical lymphoedema.  相似文献   
996.
997.
Background Chromium allergy has traditionally been caused by occupational skin contact with cement. In 1983, Danish legislation made the addition of ferrous sulphate compulsory in cement to reduce the water‐soluble chromium content to not more than 2 ppm. An effect from this intervention has previously been demonstrated among Danish construction workers. Objectives To investigate the development of chromium allergy among patients with dermatitis tested between 1985 and 2007 in Denmark. Furthermore, to determine causative exposures in patients with chromium allergy. Patients and methods A retrospective analysis of patch test data was performed (n = 16 228) and charts from patients with chromium allergy were reviewed. Comparisons were made using a χ2 test. Logistic regression analyses were used to test for associations. Results The prevalence of chromium allergy decreased significantly from 3·6% in 1985 to 1% in 1995 (Ptrend < 0·001) but increased to 3·3% in 2007 (Ptrend < 0·001). The frequency of clinically relevant cement exposure decreased significantly among patients with chromium allergy from 12·7% in 1989–1994 to 3·0% (P < 0·01) in 1995–2007, whereas the frequency of relevant leather exposure increased significantly from 24·1% during 1989–1994 to 45·5% during 1995–2007 (P < 0·02). Conclusions Chromium allergy is currently increasing in Denmark due to leather exposure.  相似文献   
998.
999.
1000.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号